Drug Trial Radar · NCT01901003
Sedative Premedication: Efficacy On Patient Experience
Last checked: Nov 19, 2026Latest source record: Apr 21, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,200
Actual
Start
Nov 2012
Primary completion
Jun 2014
Study completion Jun 2014
Sponsor
- Lead sponsor
- Assistance Publique Hopitaux De MarseilleAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 17, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Seven French university hospitals will participate in this multicentric prospective, blinded and randomized study. The investigators designed 3 study groups: Lorazepam 2.5mg, Placebo (microcrystalline celluloses) and no premedication at all. The third group (no premedication) is necessary in order to evaluate a placebo response, which may be significant on anxiety level and patients perceptions of care. It was calculated that 969 patients had to be included in order to obtain a 5 point difference between groups on the EVAN score with 80 % statistical power, leading to the inclusion of 1200 patients with an estimated maximum dropout rate of 15 %. All adults below 70 years and scheduled for elective surgery under general anesthesia can be included after information by an anesthesiologist in charge of the study and written informed consent. Non inclusion criterions are: a weight below 45 Kg, a counter indication to benzodiazepine, surgeries that could impair cognitive functions (cardiac or neurologic surgery), usual use of neuroleptics or lithium, drug addiction or former cognitive disease. The technique of anesthesia will be decided by the attending anesthesiologist, who will be unaware of the premedication technique, independently of the study protocol.
Conditions
- Perioperative Anxiety
Interventions
LorazepamDrug
no premedicationOther
Placebo (microcrystalline celluloses)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- the EVAN scoreTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Assistance Publique Hopitaux de Marseille
Marseille, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.